StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Provectus Biopharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$2.43M. For fiscal 2025 it was -$3.33M. The highest annual figure on record is -$1.01M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$3.33M–
FY2024Dec 31, 2024-$3.28M–
FY2023Dec 31, 2023-$2.57M–
FY2022Dec 31, 2022-$3.04M–
FY2021Dec 31, 2021-$1.01M–
FY2020Dec 31, 2020-$4.09M–
FY2019Dec 31, 2019-$6.19M–
FY2018Dec 31, 2018-$5.20M–
FY2017Dec 31, 2017-$10.35M–
FY2016Dec 31, 2016-$21.94M–
FY2015Dec 31, 2015-$17.41M–
FY2014Dec 31, 2014-$13.85M–
FY2013Dec 31, 2013-$9.89M–
FY2012Dec 31, 2012-$11.26M–
FY2011Dec 31, 2011-$17.20M–
FY2010Dec 31, 2010-$13.73M–
FY2009Dec 31, 2009-$8.60M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$358.25K–
Q1 FY2026Mar 31, 2026-$357.57K–
Q4 FY2025Dec 31, 2025-$869.55K–
Q3 FY2025Sep 30, 2025-$839.87K–
Q2 FY2025Jun 30, 2025-$523.13K–
Q1 FY2025Mar 31, 2025-$1.09M–
Q4 FY2024Dec 31, 2024-$912.01K–
Q3 FY2024Sep 30, 2024-$565.00K–
Q2 FY2024Jun 30, 2024-$762.59K–
Q1 FY2024Mar 31, 2024-$1.04M–
Q4 FY2023Dec 31, 2023-$561.21K–
Q3 FY2023Sep 30, 2023-$768.87K–
Q2 FY2023Jun 30, 2023-$617.78K–
Q1 FY2023Mar 31, 2023-$624.11K–
Q4 FY2022Dec 31, 2022-$754.79K-146.5%
Q3 FY2022Sep 30, 2022-$816.58K–
Q2 FY2022Jun 30, 2022-$877.89K–
Q1 FY2022Mar 31, 2022-$592.22K–
Q4 FY2021Dec 31, 2021$1.62M–
Q3 FY2021Sep 30, 2021-$815.66K–
Q2 FY2021Jun 30, 2021-$706.14K–
Q1 FY2021Mar 31, 2021-$1.11M–
Q4 FY2020Dec 31, 2020-$957.56K–
Q3 FY2020Sep 30, 2020-$1.44M–
Q2 FY2020Jun 30, 2020-$967.77K–
Q1 FY2020Mar 31, 2020-$716.32K–
Q4 FY2019Dec 31, 2019-$1.14M–
Q3 FY2019Sep 30, 2019-$1.49M–
Q2 FY2019Jun 30, 2019-$1.49M–
Q1 FY2019Mar 31, 2019-$2.07M–
Q4 FY2018Dec 31, 2018-$810.28K–
Q3 FY2018Sep 30, 2018-$919.50K–
Q2 FY2018Jun 30, 2018-$1.74M–
Q1 FY2018Mar 31, 2018-$1.74M–
Q4 FY2017Dec 31, 2017-$2.47M–
Q3 FY2017Sep 30, 2017-$2.29M–
Q2 FY2017Jun 30, 2017-$2.36M–
Q1 FY2017Mar 31, 2017-$3.23M–
Q4 FY2016Dec 31, 2016-$4.01M–
Q3 FY2016Sep 30, 2016-$5.00M–

More Provectus Biopharmaceuticals figures

See a number that looks wrong?